Jun 2026 (Q2 FY26) — Aug 12, 2026
SeaStar Medical Q2 FY26 — Pediatric AKI Adoption and Adult Trial Progress
Read the full callSeaStar Medical (ICU) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
SeaStar Medical earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.62 | +82.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -616.4 | −96.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -3.7 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$3.06 +1.66% · +$0.05
Performance −46.2% 1Y
1Y: $5.69 on 14 Oct 2025 → $3.06. High $6.37 (15 Oct 2025), low $2.21 (23 Mar 2026).
- Previous close
- $3.01
- 52-week range
- $2.21 – $6.37
- One year
- −51.96%
Overview
- Symbol
- ICU
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
SeaStar Medical earnings calls (ICU)
Financials
What the filings say
Net profit, year on year: −86% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | -4 | -5 | -4 | -2 | -4 | -3 | -4 | -4 |
| Operating margin | −6552.9% | −7114.9% | −1304.4% | −519.5% | −1955.7% | −718.6% | −727.9% | −616.4% |
| Other income | -0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 |
| Interest | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -4 | -4 | -4 | -2 | -3 | -3 | -4 | -4 |
| Tax rate | 0.0% | 0.0% | −0.1% | 0.0% | 0.0% | 0.0% | −0.1% | 0.0% |
| Net profit | -4 | -4 | -4 | -2 | -3 | -3 | -4 | -4 |
| EPS ($ per share) | -1.10 | — | -4.38 | -1.77 | -0.13 | — | -0.90 | -0.91 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 |
| Reserves | -76 | -89 | -115 | -140 | -152 |
| Total liabilities | 3 | 24 | 17 | 7 | 4 |
| Total assets | 1 | 3 | 4 | 5 | 14 |
| Line item | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash from operations | -5 | -8 | -10 | -16 | -14 |
| Cash from investing | -106 | — | — | — | — |
| Cash from financing | 3 | 7 | 10 | 18 | 24 |
| Net cash flow | — | — | — | 2 | 10 |
Insider filings
16 filings between Dec 9, 2025 and Aug 18, 2026.
Open market
decisions to buy or sellPurchases
$8.5K
3 purchases by 2 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 13
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Messinger Michael | $7.6K | — | Aug 18, 2026 |
| Baird Jennifer A | $987 | — | Dec 19, 2025 |
Latest filings (41)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 18, 2026 | Messinger Michael Chief Financial Officer | Purchase | 750 | $2.5K |
| Jul 1, 2026 | Van Heel Kenneth Director | Award | 4,000 | $0 |
| Jul 1, 2026 | Baird Jennifer A Director | Award | 4,000 | $0 |
| Jul 1, 2026 | Vincent Bernadette N Director | Award | 4,000 | $0 |
| Jul 1, 2026 | Chung Kevin Chief Medical Officer | Award | 7,202 | $0 |
| Jul 1, 2026 | Schlorff Eric Chief Executive Officer | Award | 10,288 | $0 |
| Jul 1, 2026 | Neuman John Director | Award | 4,000 | $0 |
| Feb 6, 2026 | Towne Bradford K Principal Accounting Officer | Award | 7,500 | $0 |
| Feb 6, 2026 | Schlorff Eric Chief Executive Officer | Award | 30,000 | $0 |
| Feb 6, 2026 | Chung Kevin Chief Medical Officer | Award | 15,000 | $0 |
| Feb 6, 2026 | Baird Jennifer A Director | Award | 3,000 | $0 |
| Feb 6, 2026 | Vincent Bernadette N Director | Award | 3,000 | $0 |
| Feb 6, 2026 | Neuman John Director | Award | 3,000 | $0 |
| Feb 6, 2026 | Van Heel Kenneth Director | Award | 3,000 | $0 |
| Dec 19, 2025 | Baird Jennifer A Director | Purchase | 4,200 | $987 |
| Dec 9, 2025 | Messinger Michael Chief Financial Officer | Purchase | 14,500 | $5.1K |
| Aug 27, 2025 | Van Heel Kenneth Director | Purchase | 10,000 | $8.6K |
| Aug 26, 2025 | Van Heel Kenneth Director | Purchase | 25,000 | $22.2K |
| Aug 22, 2025 | Chung Kevin Chief Medical Officer | Purchase | 10,000 | $8.0K |
| Jul 10, 2025 | Baird Jennifer A Director | Award | 4,000 | $0 |
| Jul 10, 2025 | Van Heel Kenneth Director | Award | 4,000 | $0 |
| Jul 10, 2025 | Vincent Bernadette N Director | Award | 4,000 | $0 |
| Jul 10, 2025 | Neuman John Director | Award | 4,000 | $0 |
| Jul 1, 2025 | Chung Kevin Chief Medical Officer | Option exercise | 5,000 | $0 |
| Jul 1, 2025 | Schlorff Eric Chief Executive Officer | Option exercise | 21,667 | $0 |
| Jun 30, 2025 | Baird Jennifer A Director | Purchase | 10,000 | $4.2K |
| Jun 24, 2025 | Neuman John Director | Purchase | 40,000 | $14.4K |
| Jun 4, 2025 | Neuman John Director | Option exercise | 2,667 | $0 |
| Jun 4, 2025 | Vincent Bernadette N Director | Option exercise | 2,667 | $0 |
| Jun 4, 2025 | Van Heel Kenneth Director | Option exercise | 4,000 | $0 |
| Jun 4, 2025 | Baird Jennifer A Director | Option exercise | 2,667 | $0 |
| May 20, 2025 | Baird Jennifer A Director | Purchase | 10,000 | $12.8K |
| May 20, 2025 | Chung Kevin Chief Medical Officer | Purchase | 4,500 | $5.6K |
| Dec 11, 2024 | Neuman John Director | Purchase | 10,000 | $20.4K |
| Nov 18, 2024 | Chung Kevin Chief Medical Officer | Purchase | 4,250 | $8.5K |
| Sep 30, 2024 | Chung Kevin Chief Medical Officer | Purchase | 1,000 | $4.3K |
| Aug 30, 2024 | Green David A Chief Financial Officer | Award | 8,100 | $0 |
| Aug 15, 2024 | Neuman John Director | Purchase | 10,000 | $52.4K |
| Jun 17, 2024 | Neuman John Director | Purchase | 10,000 | $43.5K |
| Jun 14, 2024 | Neuman John Director | Purchase | 10,000 | $36.9K |
| Apr 18, 2024 | Green David A Chief Financial Officer | Award | 2,223 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for SeaStar Medical Holding Corp
Free account. Everything above stays public.
Write why you follow SeaStar Medical Holding Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading